During a study spanning nearly a decade, researchers have linked the protein clusterin — for the first time — to many different facets of cardiometabolic syndrome risk through its actions in the liver. Cardiometabolic syndrome (CMS) is a cluster of conditions occurring together that increase a person’s risk of heart disease, stroke and diabetes.